We are excited about the potential of EYP-1901 in NPDR.
“We are particularly pleased to have enrolled 77 patients in this trial, exceeding the 60 patient target, and look forward to reporting topline data in the second quarter of 2024. “We are delighted to report the completion of enrollment in the Phase 2 PAVIA clinical trial evaluating EYP-1901 as a potential nine-month treatment for NPDR,” said Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it has completed enrollment in the Phase 2 PAVIA clinical trial evaluating EYP-1901 as a potential nine-month treatment for moderate to severe non-proliferative diabetic retinopathy (NPDR). WATERTOWN, Mass., J(GLOBE NEWSWIRE) - EyePoint Pharmaceuticals, Inc. – Topline PAVIA data anticipated in 2Q 2024 – – Significant investigator and patient interest drove strong recruitment of 77 patients exceeding the 60 patient target –
0 kommentar(er)
